(2Z)-3-heptyl-2-[(Z)-3-(3-heptyl-1,3-benzoxazol-3-ium-2-yl)prop-2-enylidene]-1,3-benzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: (2Z)-3-heptyl-2-[(Z)-3-(3-heptyl-1,3-benzoxazol-3-ium-2-yl)prop-2-enylidene]-1,3-benzoxazole
• 化学式: C31H41N2O2+
• 分子量: 473.7
• InChiKey: HLNIQNWYAZOTRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.2
• 重原子数：
  35
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Targeting drug/gene carriers to irradiated tissue
  申请人：Kiani F. Mohammad

  公开号：US20050186264A1

  公开（公告）日：2005-08-25

  The present invention provides targeted delivery systems to deliver pharmaceuticals to irradiated tissue comprising a biomolecule carrier, a targeting moiety to cellular adhesion molecules and a pharmaceutical. The present invention also provides methods of selectively targeting endothelial tissue for delivery of a pharmaceutical thereto and of treating a pathophysiological state in an individual using the targeted delivery systems disclosed herein. Further provided is a method of optimizing an immunoliposome for specific targeting of a pharmaceutical encapsulated therein to irradiated tissue by selecting a liposome that has a greater rate of adhesion to the irradiated tissue than a rate of uptake by the reticuloendothelial system.

  本发明提供了向照射组织输送药物的靶向输送系统，该系统包括生物大分子载体、细胞粘附分子靶向分子和药物。本发明还提供了选择性靶向内皮组织递送药物的方法，以及使用本发明公开的靶向递送系统治疗个体病理生理状态的方法。本发明还提供了一种优化免疫脂质体的方法，通过选择一种与辐照组织的粘附率大于网状内皮系统吸收率的脂质体，将其中封装的药物特异性靶向辐照组织。
• Method of Selecting a Cardiomyoctye Using Intracellular Mitochondria as an Indicator
  申请人：Hattori Fumiyuki

  公开号：US20080090266A1

  公开（公告）日：2008-04-17

  The invention relates to methods of selecting a cardiomyocyte from a cell population derived from a whole heart or a differentiated cell population derived from a stem cell without genetic alteration. Specifically, the invention relates to a method of selecting a cardiomyocyte from a cardiomyocyte-containing cell mixture without genetic alteration of a cardiomyocyte, on the basis of a relative content of cellular mitochondria and/or a relative mitochondrial transmembrane potential of the cell. The invention also relates to methods of enriching a cardiomyocyte from a cardiomyocyte-containing cell mixture without genetic alteration of a cardiomyocyte, producing a cardiomyocyte without genetic alteration of a cardiomyocyte, and evaluating the ratio of a cardiomyocyte in a cardiomyocyte-containing cell mixture.
• CANCER CELL INHIBITORY DRUG AND CANCER STEM-CELL DETECTION PROBE
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20150182518A1

  公开（公告）日：2015-07-02

  An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient.
• METHOD OF DETECTING CANCER STEM CELL, METHOD OF SCREENING CANCER STEM CELL, AND METHOD OF INHIBITING CANCER STEM CELL
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20170340622A1

  公开（公告）日：2017-11-30

  An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient
• US8623649B2
  申请人：——

  公开号：US8623649B2

  公开（公告）日：2014-01-07